BridgeBio to Present New Infigratinib Data in Achondroplasia
PALO ALTO, Calif., September 2, 2026 BridgeBio Pharma, Inc. announced plans to present new clinical data on the impact...
Gene Silencing
Advertisement
uniQure Submits BLA for AMT-130 in Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM, September 2, 2026 uniQure N.V. announced the submission of a Biologics License Application (BLA) to...
AstraZeneca Reports Wainua Phase III ATTR-CM Trial Results
CAMBRIDGE, United Kingdom, July 9, 2026 AstraZeneca and Ionis Pharmaceuticals have announced results from the Phase III CARDIO-TTRansform trial...
Novartis Del-Brax Shows Breakthrough Potential in FSHD
BASEL, Switzerland, June 11, 2026 Novartis has announced positive results from the FORTITUDE Phase I/II clinical study evaluating delpacibart...
Phio Pharmaceuticals Advances siRNA Immunotherapy in Skin Cancer with INTASYL PH-762
Dateline — King of Prussia, Pennsylvania, November 7, 2025:Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has announced new clinical data from...
Advertisements
Phio Pharmaceuticals Strengthens Governance with New Lead Director
King of Prussia, Pennsylvania – October 31, 2025 — Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing...
Arrowhead Pharma and Novartis Advance RNAi Therapy for Parkinson’s
Pasadena, CA – October 21, 2025 – Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has officially completed its global licensing and...
Advertisement
